Company Overview
Alumis Inc. operates as a clinical stage biopharmaceutical company dedicated to the development and commercialization of therapeutic medicines specifically designed for patients suffering from autoimmune disorders. The company functions within the broader healthcare sector, with its specific operational focus placed in the biotechnology industry, a field characterized by high research and development costs and reliance on successful clinical trials before product approval. In terms of scale, Alumis Inc. holds a market capitalization of $3.16B while generating annual revenue of $22.12M and employing 221 individuals. This specific combination of a multi-billion dollar market cap alongside relatively modest revenue of $22.12M indicates that the company's valuation is driven primarily by the potential future value of its clinical asset, ESK-001, rather than current cash flow generation. The significant disparity between the $3.16B market cap and the $22.12M in annual revenue suggests that the market is pricing in substantial future commercial potential from its pipeline, specifically regarding the treatment of plaque psoriasis and systemic lupus erythematosus, despite the current lack of profitable operations.
Financial Health
The company reported revenue of $22.12M for the trailing twelve months, yet it recorded a net income of $-245,152,992, revealing a cost structure where expenses far exceed the top-line revenue, which is typical for clinical-stage entities but highlights significant operational burn. The EBITDA for the period stands at $-439,332,000, further illustrating the substantial capital intensity required to advance clinical assets through development phases. Free cash flow is reported at $-190,766,128, indicating that the company is burning through cash reserves to fund its operations and research rather than generating liquidity from daily business activities. Despite these negative cash flow figures, the company maintains a cash balance of $377.72M, which provides a substantial buffer against its total debt of $37.80M. The balance sheet reflects a leveraged position with a debt-to-equity ratio of 9.82, meaning that for every dollar of equity, there are nearly ten dollars of debt, though the high cash balance mitigates immediate solvency concerns. Liquidity is strong as evidenced by a current ratio of 6.01, which indicates that the company possesses more than six dollars of current assets for every dollar of current liabilities, ensuring ample short-term liquidity. Return on Equity is -66.9% and Return on Assets is -61.5%, metrics that reveal that management effectiveness is currently measured by the rate of capital deployment rather than profitability, as both equity and assets are generating negative returns due to pre-revenue status.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -8.18, a metric that implies expected earnings are still negative in the near future but suggests the market anticipates a turnaround or positive earnings contribution eventually. The price-to-book ratio is 6.88, which indicates a significant market premium over the company's book value, reflecting investor confidence in the intellectual property and clinical pipeline rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 143.06 and an EV/EBITDA of -5.26 suggest that the stock is priced based on sales potential and clinical milestones rather than traditional profitability multiples. The 52-week high is $30.60 and the 52-week low is $2.76, placing the current trading environment within a wide range that reflects high volatility associated with biotechnology stocks. The beta value is N/A, which means the stock's price volatility relative to the broader market cannot be quantified by historical beta, a common situation for smaller biotech firms where price swings are often driven by specific clinical trial results or regulatory news rather than broad market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company has not yet reached a stage of consistent commercial scaling where comparable growth rates can be calculated from prior periods. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, or in this case, the capital resources, are reinvested into growth initiatives such as clinical trials and drug development rather than distributed to shareholders. The absence of a dividend program aligns with the clinical stage nature of the business, where capital retention is essential for advancing the ESK-001 asset through regulatory pathways. Overall, the growth and income profile is defined entirely by the potential for future commercialization of autoimmune therapies, with no current income generation or historical growth rates available for analysis.